LT2480224T - Farmacinė kompozicija, skirta mcp-1 medijuojamų uždegiminių ligų gydymui - Google Patents

Farmacinė kompozicija, skirta mcp-1 medijuojamų uždegiminių ligų gydymui

Info

Publication number
LT2480224T
LT2480224T LTEP10747897.6T LT10747897T LT2480224T LT 2480224 T LT2480224 T LT 2480224T LT 10747897 T LT10747897 T LT 10747897T LT 2480224 T LT2480224 T LT 2480224T
Authority
LT
Lithuania
Prior art keywords
mcp
treatment
pharmaceutical composition
inflammatory diseases
mediated inflammatory
Prior art date
Application number
LTEP10747897.6T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Beatrice Garrone
Alessandro BLE`
Giuseppe Biondi
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of LT2480224T publication Critical patent/LT2480224T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
LTEP10747897.6T 2009-09-23 2010-09-03 Farmacinė kompozicija, skirta mcp-1 medijuojamų uždegiminių ligų gydymui LT2480224T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23
PCT/EP2010/062979 WO2011036047A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
LT2480224T true LT2480224T (lt) 2017-08-25

Family

ID=41722750

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10747897.6T LT2480224T (lt) 2009-09-23 2010-09-03 Farmacinė kompozicija, skirta mcp-1 medijuojamų uždegiminių ligų gydymui

Country Status (25)

Country Link
US (1) US9492542B2 (lt)
EP (1) EP2480224B1 (lt)
JP (2) JP2013505278A (lt)
KR (1) KR101774402B1 (lt)
CN (1) CN102573827B (lt)
AR (1) AR078307A1 (lt)
AU (1) AU2010297405B2 (lt)
BR (1) BR112012006149A2 (lt)
CA (1) CA2760180C (lt)
CY (1) CY1119125T1 (lt)
DK (1) DK2480224T3 (lt)
EA (1) EA021485B1 (lt)
ES (1) ES2637024T3 (lt)
GE (1) GEP20146067B (lt)
HR (1) HRP20171209T1 (lt)
HU (1) HUE033102T2 (lt)
IL (1) IL218001A (lt)
LT (1) LT2480224T (lt)
MX (1) MX347957B (lt)
PL (1) PL2480224T3 (lt)
PT (1) PT2480224T (lt)
SG (2) SG10201405408YA (lt)
SI (1) SI2480224T1 (lt)
UA (1) UA108742C2 (lt)
WO (1) WO2011036047A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2262778T (lt) 2008-03-07 2019-11-11 Acraf 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška
AR070813A1 (es) 2008-03-07 2010-05-05 Acraf Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK356085A (da) 1984-08-06 1986-02-07 Upjohn Co Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (lt) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
EP1389105A4 (en) 2001-05-14 2005-08-17 Merck & Co Inc METHOD OF TREATMENT
US20030065019A1 (en) 2001-09-19 2003-04-03 Francois Mach Treatment of rheumatoid arthritis with statins (HMG-CoA reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
EP1806137A4 (en) 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
ES2448424T3 (es) 2006-02-07 2014-03-13 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la recurrencia de accidente cerebrovascular
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
LT2262778T (lt) 2008-03-07 2019-11-11 Acraf 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška
AR070813A1 (es) 2008-03-07 2010-05-05 Acraf Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1
EP2254869B1 (en) 2008-03-07 2017-05-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40

Also Published As

Publication number Publication date
PL2480224T3 (pl) 2017-10-31
JP2013505278A (ja) 2013-02-14
AU2010297405A1 (en) 2012-03-01
JP2016028026A (ja) 2016-02-25
US20120220636A1 (en) 2012-08-30
MX2012003485A (es) 2012-04-19
EP2480224A1 (en) 2012-08-01
ES2637024T3 (es) 2017-10-10
AR078307A1 (es) 2011-10-26
AU2010297405B2 (en) 2016-05-26
JP6122470B2 (ja) 2017-04-26
SI2480224T1 (sl) 2017-10-30
EA021485B1 (ru) 2015-06-30
MX347957B (es) 2017-05-16
DK2480224T3 (en) 2017-09-04
BR112012006149A2 (pt) 2016-06-28
CN102573827B (zh) 2016-08-31
CA2760180A1 (en) 2011-03-31
SG178414A1 (en) 2012-03-29
HRP20171209T1 (hr) 2017-10-20
CA2760180C (en) 2017-07-25
CY1119125T1 (el) 2018-02-14
IL218001A (en) 2015-10-29
EP2480224B1 (en) 2017-05-24
KR20120090988A (ko) 2012-08-17
EA201270449A1 (ru) 2012-08-30
US9492542B2 (en) 2016-11-15
UA108742C2 (uk) 2015-06-10
KR101774402B1 (ko) 2017-09-04
CN102573827A (zh) 2012-07-11
HUE033102T2 (en) 2017-11-28
IL218001A0 (en) 2012-04-30
GEP20146067B (en) 2014-03-25
WO2011036047A1 (en) 2011-03-31
SG10201405408YA (en) 2014-10-30
PT2480224T (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
HRP20141057T1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
EP2564845A4 (en) MEDICINE FOR TREATING HYPERPLASIC AND INFLAMMATORY DISORDERS IN HUMANS BASED ON DIINDOLYLMETHANE
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
PT2429507T (pt) Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
HK1171677A1 (en) Composition for the treatment of hemorrhoids and related diseases
IL218001A0 (en) Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
PT2328553T (pt) Corticosteroides para o tratamento de doenças inflamatórias do trato gastrointestinal
EP2416803A4 (en) NEW METHODS OF TREATING INFLAMMATORY DISEASES
IL200753A (en) Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
EP2767286A4 (de) Orale pharmazeutische zusammensetzung zur behandlung von entzündlichen magen-darm-erkrankungen
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases